Anglo-Dutch oil supermajor Royal Dutch Shell PLC (NYSE: RDS-A) announced Monday that it will sell its assets in the Eagle Ford shale play in south Texas. The sale follows an announcement in August that Shell would write down $2.1 billion in the value of its North American assets.
Shell holds leases on 106,000 acres in the Eagle Ford play and currently operates 192 wells in the region. But the company did not acquire the leases until 2010, by which time the price of natural gas had begun falling. Shell said its Eagle Ford assets did not meet the company’s targets for scale and profitability.
When the company took the write-down on its North American assets, it laid the blame squarely on the low price of natural gas. At the same time, the company dropped its production targets for oil production from the shale formations. The writing was on wall at that point.
Some natural gas producers, like Exxon Mobil Corp. (NYSE: XOM) and Chesapeake Energy Corp. (NYSE: CHK), have successfully ridden recent high oil prices from the liquids-rich plays in the Eagle Ford play. Shell has been unable to do so.
Best Low Price Stocks For 2014: Enzo Biochem Inc. (ENZ)
Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory, a network of approximately 30 patient service centers, a laboratory, and a full-service phlebotomy and in-house logistics department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It provides proteins, antibodies, peptides, small molec ules, labeling probes, dyes, and kits, which offer tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts primarily in the field of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment researches and develops therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company sells its products through its direct sales force; and a network of distributors worldwide. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Advisors' Opinion:- [By CRWE]
Enzo Biochem Inc. (NYSE:ENZ) is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards.
Best Low Price Stocks For 2014: Zimmer Holdings Inc.(ZMH)
Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. The company offers orthopedic reconstructive devices that restore function lost due to disease or trauma in joints such as knees, hips, shoulders, and elbows; dental reconstructive implants, which restore function and aesthetics in patients who have lost teeth due to trauma or disease; spinal devices that are utilized by orthopedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities, and trauma in various regions of the spine; and trauma devices used primarily to reattach or stabilize damaged bone and tissue to support the body?s natural healing process. It also provides surgical products comprising surgical supplies and instruments designed to aid in orthopedic surgical proce dures and post-operation rehabilitation. In addition, the company offers healthcare consulting services. Its customers include orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, and healthcare dealers, as well as agents, healthcare purchasing organizations, or buying groups. The company was founded in 1927 and is headquartered in Warsaw, Indiana.
Advisors' Opinion:- [By Dan Carroll]
The industry's way of the future
Emerging market trauma buys isn't a new trend. Smith & Nephew follows in the footsteps of Stryker (NYSE: SYK ) , its fellow orthopedics player that spent $764 million on purchasing China's largest trauma business, Trauson Holdings, back in January. Zimmer Holdings (NYSE: ZMH ) also took a step into China's orthopedics market, purchasing Chinese�firm Montagne back in 2010 to push its own emerging market expansion. - [By Steve Symington]
Of course, Biomet is a privately held company, but it's safe to say that trials like this should have other publicly traded companies like Stryker (NYSE: SYK ) , Zimmer (NYSE: ZMH ) , and Johnson & Johnson (NYSE: JNJ ) sweating bullets given their competing manually placed implants. It also doesn't help their case that Johnson & Johnson in March lost its first of 10,750 lawsuits over defective metal-on-metal hip implants, but you can bet MAKO can't wait to capitalize on the fallout with its own innovative offerings.
Top Biotech Stocks To Watch Right Now: Tag Pacific Ltd (TAG)
Tag Pacific Limited is an investor. The Company segments include: power investments, which consists of MPower Group Pty Limited, MPower Business Services Pty Ltd, MPower Products Pty Ltd, MPower Pacific Ltd, MPower Projects Pty Ltd, MPower Solar Systems Pty Ltd and MPower Nominees Pty, and other investments, which consists of principally of its investments in the Power Property Unit Trust. Power investments segment is a provider of power solutions for use in emergency, back-up, generated and renewable power situations in Australia, New Zealand and the Pacific Islands. In August 2012, it announced that its power systems subsidiary MPower Projects Pty Limited acquired certain assets of the business, Direct Engineering Services Marine and Offshore. On February 29, 2012, it terminated its Comprador Pacific Unit Trust. Its investment in Unique World Group Pty Limited was sold on December 2, 2011. Its investment in iSoft Group Limited was sold on July 18, 2011.Best Low Price Stocks For 2014: Territorial Bancorp Inc.(TBNK)
Territorial Bancorp Inc. operates as the bank holding company for Territorial Savings Bank, a federally-chartered savings bank that provides a range of financial services to individuals, families, and businesses in Hawaii. It involves in accepting deposits from the general public and investing those deposits together with funds generated from operations and borrowings in loans and investment securities. The company?s deposit products include passbook and statement savings accounts, certificates of deposits, money market accounts, commercial and regular checking accounts, and NOW accounts. Its loan products include one-to-four-family residential mortgage loans; home equity loans and lines of credit; construction, commercial, and other non-residential real estate loans; consumer loans; and multi-family mortgage loans. The company, through its subsidiary, Territorial Financial Services, Inc., also engages in insurance agency activities. In addition, it provides various non-d eposit investments, including annuities and mutual funds through a third-party broker-dealer. As of December 31, 2010, the company operated 26 full-service branch offices in Hawaii. The company was founded in 1921 and is headquartered in Honolulu, Hawaii.
Advisors' Opinion:- [By Lisa Levin]
Territorial Bancorp (NASDAQ: TBNK) shares touched a new 52-week low of $21.31. Territorial Bancorp shares have dropped 9.43% over the past 52 weeks, while the S&P 500 index has gained 16.18% in the same period.
No comments:
Post a Comment